Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ziyin Yangshen decoction granules
- Development stage
- Phase 1
- Lead developer
- Shuguang Hospital
- Administration
- Oral
01
Overview
Ziyin Yangshen decoction granules is a Traditional Chinese Medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is designed to treat heart failure with preserved ejection fraction (HFpEF) by applying the TCM principles of nourishing Yin and tonifying the kidney (or tranquilizing the spirit). The drug is currently being evaluated in a randomized, double-blind, placebo-controlled multicenter Phase 1 clinical trial in China. In this study, it is administered alongside standard therapy to assess its efficacy in improving 180-day cardiovascular outcomes and symptoms, as well as its impact on multi-omics biomarkers in patients with HFpEF.
- Other names
- Ziyin Yangshen decoction granules
Beyond the preview
Go deeper on Ziyin Yangshen decoction granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ziyin Yangshen decoction granules.